| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.8 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.9 |